2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1692

Validation of a Two-Question Patient Reported Outcome Measure for Psoriasis
Abstract Number: 1693

Chronic Back Pain in Early Psoriatic Arthritis
Abstract Number: 1694

Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Abstract Number: 1695

Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Abstract Number: 1696

Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Abstract Number: 1697

Validity of Diagnostic Codes and Point Prevalence of Psoriatic Arthritis in Israel – a Population-Based Study
Abstract Number: 1698

Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Abstract Number: 1699

RAPID3 Near Remission Shows Good Agreement with Minimal Disease Activity Criteria in Psoriatic Arthritis
Abstract Number: 1700

Treating Psoriatic Arthritis (PsA) to Target: Defining Psoriatic Arthritis Disease Activity Score (PASDAS) That Reflects Disease Activity in Psa
Abstract Number: 1701

The Presence of Depression Might be an Important Determinant of Achieving Minimal Disease Activity State in Psoriatic Arthritis
Abstract Number: 1702

Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1703

Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Abstract Number: 1704

Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses
Abstract Number: 1705

The Risk of Fracture Among Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Number: 1706

Quality of Life at Baseline in Early Psoriatic Arthritis Related to Disease Domains

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].